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Abstract (max 250 words) 
 
Inhibitors of the tyrosine kinase Btk have been proposed as novel antiplatelet agents. In 
this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-
mediated activation and tyrosine phosphorylation including Syk and PLCγ2 in human 
platelets. Activation is also blocked in patients with X-linked agammaglobulinaemia (XLA) 
caused by a deficiency or absence of Btk. In contrast, the response to GPVI is delayed in 
the presence of low concentrations of ibrutinib or in patients with XLA, and tyrosine 
phosphorylation of Syk is preserved. A similar set of results is seen with the second-
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generation inhibitor, acalabrutinib. The differential effect of Btk inhibition in CLEC-2 relative 
to GPVI signalling is explained by the positive feedback role involving Btk itself, as well as 
ADP and thromboxane A2 mediated activation of P2Y12 and TP receptors, respectively. This 
feedback role is not seen in mouse platelets and, consistent with this, CLEC-2-mediated 
activation is blocked by high but not by low concentrations of ibrutinib. Nevertheless, 
thrombosis was absent in 8 out of 13 mice treated with ibrutinib. These results show that Btk 
inhibitors selectively block activation of human platelets by CLEC-2 relative to GPVI 
suggesting that they can be used at ‘low dose’ in patients to target CLEC-2 in thrombo-
inflammatory disease. 
 
Introduction 
 
The C-type lectin receptor CLEC-2 is expressed at high levels on platelets and at low 
levels on a sub-population of haematopoietic cells1. Its only known physiological ligand is 
podoplanin2. Recent reports have demonstrated a critical role for CLEC-2 in inflammation-
driven venous thrombosis3,4, generating interest in drugs that target CLEC-2 in thrombo-
inflammatory disorders whilst preserving haemostasis. This is further fuelled by the 
demonstration that CLEC-2 plays a minimal or negligible role in haemostasis (for review see 
Rayes et al5). 
CLEC-2 has a cytoplasmic tail containing a single tyrosine in a conserved YxxL 
sequence in a motif that represents half of an immunoreceptor tyrosine-based activation 
motif (ITAM), known as a hemITAM. The conserved tyrosine is phosphorylated by the 
tyrosine kinase Syk6. This leads to recruitment of Syk through binding of its tandem SH2 
domains and initiation of a downstream signalling cascade involving Src, Syk and Tec 
(including Btk) kinases, various adapter proteins including LAT, Gads, Grb-2 and SLP-76, 
the Vav family GTP exchange proteins and the effector protein, PLCγ27-9. This hemITAM 
signalling pathway is similar to that used by the YxxL-containing platelet ITAM receptors 
such as the collagen receptor GPVI-FcRγ complex and the low affinity immune receptor 
FcγRIIA10. A fundamental difference in these pathways however is that Syk binds to two 
phosphorylated tyrosines within a single ITAM in GPVI-FcRγ and FcγRIIA, and to two 
phosphorylated hemITAMs in separate cytosolic receptor chains of CLEC-211. A further 
difference between CLEC-2 and GPVI signalling in human platelets is the critical 
dependence of CLEC-2 on positive feedback signalling through ADP and thromboxane A2 
(TxA2), actin polymerisation, and the small GTPase Rac8. In contrast these positive 
feedback pathways play a relatively minor role in CLEC-2 signalling in mouse platelets12. 
Recently, irreversible inhibitors of the Tec kinase Btk have entered clinical use for the 
treatment of B-cell malignancies13,14. These include the first-generation inhibitor ibrutinib and 
the second-generation inhibitor acalabrutinib. Ibrutinib is associated with a significant 
increase in major bleeding which is much reduced with the second generation inhibitor 
acalabrutinib14,15. Patients with X-linked agammaglobulinaemia (XLA) who have function-
disrupting mutations or loss of Btk however do not have increased bleeding. This 
observation, coupled with protein biochemistry measurements, have led us to conclude that 
the bleeding induced by ibrutinib is due to the high dosing strategy and off-target effects16. 
Platelets express two members of the Tec family of tyrosine kinases, namely Btk and Tec. 
Btk has an approximate 10-20 fold greater level of expression in both human and mouse 
platelets17,18. Various studies have shown redundancy between the two kinases downstream 
of GPVI, with Tec able to partially compensate for the absence of Btk in human platelets 
from patients with XLA and in mouse platelets which are deficient in Btk16,19,20.  
Recently, Btk inhibitors have been proposed to represent a new class of anti-thrombotic 
drug (reviewed by Busygina et al21.) based on the observation that they delay or inhibit ex 
vivo platelet activation by GPVI16,22-24 and by immobilised atherosclerotic plaque at arterial 
rates of flow25. In addition, Btk inhibitors block platelet activation by CLEC-2. However, in 
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contrast to GPVI, Manne et al. have proposed that Btk lies upstream of Syk in the CLEC-2 
signalling cascade based on studies using ibrutinib-treated human platelets26. 
In the present study, we demonstrate that the results of Manne et al. are explained by 
the positive feedback role of ADP and TxA2 and that concentrations of ibrutinib that have 
little or no effect on the response to GPVI stimulation selectively block activation by CLEC-2. 
This observation, together with the pivotal role of CLEC-2 in thrombo-inflammation, suggests 
that inhibitors of Btk represent new antiplatelet agents for thrombo-inflammatory disorders 
with minimal effect on haemostasis. 
Methods 
Platelet preparation 
Blood was taken from consenting patients or healthy, drug-free volunteers, into 4% 
sodium citrate as previously described16. Mouse blood was drawn from CO2 asphyxiated 
mice following isoflurane anaesthesia by inferior vena cava (IVC) puncture and taken into 
acid citrate dextrose (ACD). Platelet rich plasma (PRP) was obtained by centrifugation. 
Washed human and mouse platelets were obtained by further centrifugation of PRP in the 
presence of prostacyclin and resuspended in modified Tyrode’s buffer as previously 
described16. Platelets were used at a cell density of 4x108/ml for aggregometry and 
biochemical studies.  
Light transmission aggregometry (LTA) 
Aggregation was monitored by light transmission using a Model 700 aggregometer 
(Chronolog, Havertown, PA, USA) as previously described16. 
Protein phosphorylation 
Eptifibatide treated washed platelets were stimulated in a Model 700 aggregometer in 
the presence of ibrutinib or vehicle as described16. Activation was terminated after 300 
seconds by addition of reducing sample buffer. This was followed by lysate separation by 
SDS-PAGE, electro-transfer and western blot as described previously16. 
 
IVC stenosis assay 
All mouse experiments were performed using wild type (WT) mice on a C57Bl/6 genetic 
background under Home Office project licences P0E98D513 and PC427E5DD. Mice were 
sourced from Charles River UK Ltd. (Margate, UK). For ex vivo platelet function assays and 
in vivo thrombosis assays 8 week old C57Bl/6 WT male mice were treated by intraperitoneal 
(IP) injection with a total dose of 140 mg/kg of ibrutinib or vehicle (5% DMSO, 30% 
Polyethylene glycol 300, 5% Tween 20, 60% deionised water) in divided doses once daily 
over 2 – 4 days. Blood was taken at the stated times and platelet function analysis was 
performed as described above using flow cytometry. 
The IVC stenosis model was performed as described by Payne et al3. In brief, mice were 
anaesthetised using isoflurane and then a laparotomy was performed. Side branches of the 
IVC were identified and tied off before the IVC itself was stenosed with a ligature and a 30-
gauge spacer to maintain a small degree of vessel patency. The incision was then closed 
and mice were allowed to recover from surgery. Buprenorphine was used pre- and post-
operatively for analgesia. Mice were then culled 48 hours after the surgery and the IVC was 
examined for the presence and size of thrombus. 
 
 
Other methods 
 Details of reagents and methods used for flow cytometry, flow adhesion, imaging, image 
analysis and cell transfection are detailed in the supplementary material. 
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Statistical analysis 
All data are presented as mean ± standard error of the mean with statistical significance 
taken as p<0.05 unless otherwise stated. Statistical analysis was performed using Mann-
Whitney tests, Fisher’s exact test, Welch’s t-test or one or two-way ANOVA with corrections 
for multiple comparisons as stated. Statistical analysis of the IC50 values was performed 
using Welch’s t-test. All statistical analyses were performed using GraphPad Prism 7 
(GraphPad Software Inc. La Jolla, Ca). 
 
Ethical Approval  
Ethical approval for collecting blood from patients and healthy volunteers was granted by 
the National Research Ethics Service (10/H1206/58) and Birmingham University Internal 
Ethical Review (ERN_11-0175) respectively. Work on patients with XLA has ethical approval 
via the University of Birmingham Human Biomaterials Resource Centre (16-251 Amendment 
3). 
 
Results 
CLEC-2-mediated human platelet aggregation is inhibited by low concentrations of 
Btk inhibitors 
To examine the role of Btk downstream of platelet CLEC-2 in humans we took healthy 
donor washed platelets and added increasing concentrations of ibrutinib before stimulating 
with the CLEC-2 agonist rhodocytin. As shown in Figure 1A-B, ibrutinib completely inhibited 
CLEC-2-mediated aggregation at concentrations as low as 70 nM. Inhibition was marked 
after 5 min incubation with ibrutinib and only increased slightly with times up to 60 min 
(Figure 1A-B and Supplementary Figure 1). Strikingly, the IC50 for inhibition was over 20-fold 
lower than that required to block GPVI-mediated platelet aggregation16 (Table 1). This 
selective inhibition of the response to CLEC-2 activation is consistent with the results of 
Manne et al26. 
We further studied the effect of in vivo Btk inhibition on PRP obtained from patients with 
chronic lymphocytic leukaemia (CLL) treated with ibrutinib or the more specific second 
generation Btk inhibitor acalabrutinib. Unlike platelets from patients treated with a control 
chemotherapy regimen (fludarabine, cyclophosphamide and rituximab; FCR), Btk inhibitor 
treated patients did not aggregate to even high levels of CLEC-2 stimulation (Figure 1C). We 
have previously shown that PRP from Btk inhibitor-treated patients do, however, aggregate 
to GPVI and G protein-coupled receptor (GPCR) stimulation16. 
 
Adhesion to podoplanin under venous flow conditions is abrogated by Btk inhibition 
 Given the role of platelet CLEC-2 and podoplanin in the thrombo-inflammatory and 
venous thrombosis models performed by Hitchcock et al4 and Payne et al3 we investigated 
whether inhibition of CLEC-2-mediated platelet function by ibrutinib reduced or prevented 
adhesion to the endogenous ligand under flow. Blood from healthy donors, patients with XLA 
or those taking ibrutinib or acalabrutinib was flowed over podoplanin at venous shear. 
Strikingly we found that both platelet adhesion and platelet aggregate size were markedly 
reduced when compared to healthy donor blood regardless of the method of Btk inhibition 
(Figure 2). 
 
Btk and Syk inhibition block CLEC-2-mediated Btk phosphorylation 
To examine the effect of ibrutinib on CLEC-2-mediated protein phosphorylation, ibrutinib-
treated washed human platelets were lysed after stimulation with rhodocytin and lysates 
probed with phosphospecific antibodies. As shown in Figure 3A, phosphorylation of Syk 
Y525/6, SLP-76 Y145, LAT Y200, Btk Y223 and Y551, and PLCγ2 Y1217 was blocked by 
70 nM ibrutinib with IC50s similar to those for aggregation (Table 1). This concentration of 
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ibrutinib reduced total phosphotyrosine to basal levels and inhibited phosphorylation on all 
measured tyrosine sites except the constitutive phosphorylation of Src Y418. Loss of Src 
pY418 was seen at higher concentrations of ibrutinib (Figure 3Aiv) similar to our previous 
study16. 
We performed similar experiments with acalabrutinib and found that Btk Y223 
phosphorylation was lost at a concentration (3 μM) that also partially inhibited 
phosphorylation of Syk (Supplementary Figure 2). This concentration caused a marked 
reduction on platelet activation by CLEC-2 but no change to platelet aggregation in response 
to GPVI ligation16 confirming the selectivity to CLEC-2. The observation, however, of partial 
phosphorylation of Syk and complete abrogation of phosphorylation of Btk in the presence of 
acalabrutinib suggests that Btk does not lie upstream of Syk in contrast to the conclusion of 
Manne et al26. 
 A further prediction in the model of Manne et al26 in which Syk lies downstream of Btk is 
that inhibition of Syk should not block phosphorylation of Btk. To test this, we incubated 
human platelets with increasing concentrations of the Syk inhibitor PRT 060318 prior to 
stimulation with rhodocytin. Lysates were then probed using phosphospecific antibodies to 
Syk pY525/6, LAT pY200, Btk pY551 and PLCγ2 pY1217. Supplementary Figure 3 shows 
that phosphorylation of Syk, LAT, Btk and PLCγ2 were lost in tandem providing further 
evidence against the model. This result is in keeping with our previous results examining 
CLEC-2-mediated phosphorylation events in mice with a Syk mutation rendering it unable to 
undergo tyrosine phosphorylation9. 
 In summary, the above results show that low concentrations of ibrutinib and acalabrutinib 
selectively block platelet activation by CLEC-2 over GPVI and provide evidence against the 
model of Manne et al. in which Btk lies upstream of Syk. 
 
ADP rescues Syk phosphorylation in the presence of Btk inhibition 
 We have previously shown that CLEC-2 signalling in human platelets is critically 
dependent on positive feedback signals from thromboxane TP and ADP P2Y12 receptors8. 
Our standard platelet preparation method leads to partial desensitisation of the ADP P2Y1 
receptor27 and loss of aggregation to ADP as a consequence of this (Supplementary Figure 
4). This may have accentuated the previously described dependency on P2Y12 receptors. To 
investigate this, we repeated the studies on aggregation and protein phosphorylation but in 
the presence of excess ADP (10 μM). Similar to the results with no added ADP, 70 nM 
ibrutinib inhibited aggregation (Figure 3Bii) and phosphorylation of Btk Y223 and PLCγ2 
Y1217 (Figure 3Bi-ii). In contrast, however, it did not inhibit phosphorylation of Syk Y525/6, 
LAT Y200 or Btk on its Src kinase phosphorylation site Y551 (Figure 3Bi and iii). The 
demonstration of phosphorylation of Syk, LAT and Btk on Y551 but absence of Btk 
autophosphorylation on Y223 in ibrutinib treated human platelets confirms that Btk lies 
downstream of Syk in the CLEC-2 signalling cascade in human platelets. 
CLEC-2-mediated platelet aggregation and tyrosine phosphorylation is blocked in 
patients with Btk mutations 
Our previous study found off-target effects of ibrutinib even when used at concentrations 
as low as 70 nM16. To investigate whether the potent inhibition of CLEC-2-mediated platelet 
activation by ibrutinib was mediated by its blockade of Btk or an off-target effect, we studied 
platelet aggregation to rhodocytin in patients with XLA. CLEC-2-mediated aggregation and 
phosphorylation of PLCγ2 Y1217 were blocked, whereas phosphorylation of Syk Y525/6 and 
LAT Y200 was only partially reduced (Figure 4). This demonstrates that the initial 
phosphorylation of Syk and LAT is independent of Btk and that this is then increased by a 
Btk-dependent pathway. 
The kinase domain of Btk is required for signalling downstream of CLEC-2 
We have previously shown that Btk supports platelet activation by GPVI through both 
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acting as a kinase and as an adapter protein16. The observation of complete loss of 
aggregation in the presence of ibrutinib and acalabrutinib however suggests the kinase 
activity of Btk is critical for activation by CLEC-2. Consistent with this, wild type but not 
kinase dead (KD) Btk restored NFAT signalling in a CLEC-2 transfected cell line model, 
which was blocked by ibrutinib and acalabrutinib (Figure 5A-C). CLEC-2 and Btk expression 
was similar regardless of the Btk construct used (Figure 5D-E). The lack of signalling with 
KD Btk confirms a fundamental difference between the role of Btk in the CLEC-2 and GPVI 
signalling pathways. 
 
Btk does not lie upstream of Syk in CLEC-2 stimulated mouse platelets 
We extended the studies to investigate of the role of Btk in CLEC-2 signalling in mouse 
platelets. In agreement with the results of Lee et al28, we found that only high concentrations 
of ibrutinib, that abrogated platelet activation by GPVI, blocked CLEC-2-mediated platelet 
aggregation (Figure 6A, Table 1 and not shown). Phosphorylation of Syk Y519/520 
(equivalent to Y525/526 in human platelets), and LAT Y132 and Y200 were preserved in the 
presence of ibrutinib (Figure 6B). This is consistent with the results in human platelets 
stimulated by CLEC-2 in the presence of ADP and further confirm that Btk does not lie 
upstream of Syk and LAT in mouse platelets. 
 
The effect of ibrutinib on deep vein thrombosis  
 We sought to establish whether ibrutinib would prevent inferior vena cava (IVC) 
thrombus formation in a mouse model of deep vein thrombosis (DVT) that is known to be 
dependent on CLEC-2. Mice were dosed with ibrutinib via intraperitoneal injection for up to 
four days. This dosing strategy blocked CLEC-2-mediated but not PAR4-mediated platelet 
activation (Figure 7A). Mice dosed with ibrutinib had a reduction in thrombus prevalence 
relative to controls (Figure 7Bi) but this was not statistically significant. In the small number 
of ibrutinib treated mice which still formed IVC thrombi, thrombus size was not significantly 
altered relative to controls (Figure 7Bii). 
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Discussion 
 The main findings from the above studies into the role of Btk downstream of CLEC-2 
receptor ligation in platelets are (i) Btk lies downstream of Syk in the CLEC-2 signalling 
cascade in human and mouse platelets in contrast to the conclusion of Manne et al.; and (ii) 
Btk inhibitors selectively block platelet activation by CLEC-2 relatively to GPVI. This 
suggests that Btk inhibitors can be used to selectively block CLEC-2-mediated platelet 
activation in thrombo-inflammation without any increase in bleeding or other side effects due 
to blockade of GPVI and ITAM receptors in other cells. 
 
 The results depicted here do not support the conclusions by Manne et al. that Btk lies 
upstream of Syk in CLEC-2 signalling in both human and mouse platelets26. While we were 
able to replicate the complete loss of whole cell tyrosine, Syk and Btk phosphorylation with 
ibrutinib in human platelets reported by Manne et al., we show that ibrutinib blocks Btk 
phosphorylation at its Src phosphorylation site (Y551) which is not in keeping with the known 
mechanism of action of ibrutinib; Btk is phosphorylated by Src at Y551 but ibrutinib then 
blocks subsequent autophosphorylation at Y223. We also report of loss of Btk 
phosphorylation using the Syk inhibitor PRT 060318. Both of these findings are inconsistent 
with a model in which Btk lies upstream of Syk. This is further supported by the observation 
that phosphorylation of Syk and Btk Y551 is restored in the presence of the secondary 
messenger ADP. These results demonstrate that the initial phosphorylation of Syk is 
independent of Btk and that this is then increased by a pathway that involves Btk and ADP. 
 Our results show that human CLEC-2-mediated platelet activation is critically 
dependent on the kinase function of Btk. Low concentrations of ibrutinib and the more Btk-
selective acalabrutinib, as well as patients treated with these inhibitors and patients with 
genetic loss-of-function mutations of Btk, have no demonstrable CLEC-2-mediated platelet 
activation, even when stimulated with very high levels of agonist. We have previously shown 
that genetic or pharmacological Btk inhibition of platelets does not result in loss of activation 
to GPVI in human platelets because; (i) Btk was able to function as an adapter downstream 
of GPVI to preserve platelet activation and (ii) Tec may be able to compensate for the lack of 
Btk kinase or adapter activity16. Here we show that Tec is not able to compensate for a lack 
of Btk in the CLEC-2 signalling cascade through studies on patients with XLA and that the 
kinase domain of Btk is critical for CLEC-2’s signalling in a transfected cell line model. 
 The present results suggest that Btk inhibitors have the potential to be used at very 
low concentrations as selective inhibitors of CLEC-2 in thrombo-inflammatory disorders with 
minimal off-target effects and no increased bleeding. Not only does Btk inhibition prevent 
platelet activation to CLEC-2 but we have shown that it also results in abrogation of platelet 
adhesion to podoplanin at venous rates of shear and a reduction in DVT formation in the 
ibrutinib treated mice. The in vivo DVT study was powered based on the rates of thrombosis 
seen in CLEC-2 deficient and WT mice in the studies of Payne et al3. The lack of statistical 
significance in the trend towards inhibition of DVT formation may reflect the fact that 
pharmacological blockade of Btk in mice did not result in full inhibition of CLEC-2 signalling 
throughout the 48 hours required for venous thrombosis in this model and the fact that, 
unlike for human CLEC-2 signalling, mouse CLEC-2 is not critically dependent on Btk. 
Interestingly the thrombi that did form in the ibrutinib-treated mice were the same size as in 
the control mice. This is consistent with a model where CLEC-2 activation is required to 
initiate thrombus formation, but not to propagate it. 
 
 
 
 
 
Conclusion 
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 In conclusion, the present study shows that Btk lies downstream of Syk in human and 
mouse platelets and shows that Btk inhibitors block human CLEC-2-mediated platelet 
function at >20-fold lower concentrations than they block GPVI signalling16 and mouse 
CLEC-2. The mechanism underlying this selectivity is because Btk kinase activity is critical 
for human platelet CLEC-2 function, but not for GPVI. This means that low dose Btk 
inhibitors could be used therapeutically to inhibit CLEC-2 in platelets without any off-target 
effects on GPVI and ITAM receptors in other haematopoietic cells. This provides a 
mechanism for selective targeting of CLEC-2 in thrombo-inflammatory disorders, such as 
DVT or infection-driven thrombosis, whilst preserving haemostasis3,4. 
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Table and Figure Legends 
 
Figure Dose Response Curve IC50 (μM) 95% C.I. 
1B HD Aggregation 0.023 0.009 — 0.053 
3Aii HD Btk pY223 0.024 0.002 — 0.133 
3Aii HD PLCγ2 pY1217 0.034 0.010 — 0.119 
3Aiii HD Syk pY525/6 0.052 0.020 — 0.150 
3Aiii HD LAT pY200 0.036 0.028 — 0.189 
3Aiii HD SLP76 pY145 0.032 0.015 — 0.066 
3Aiii HD Btk pY551 0.059 0.023 — 0.179 
3Aiv HD Src pY418 - - 
3Bii HD Aggregation (added 10 μM ADP) 0.034 0.017 – 0.07 
3Biii HD Btk pY223 (added 10 μM ADP) 0.006 0.003 — 0.009 
3Biii HD PLCγ2 pY1217 (added 10 μM ADP) 0.023 0.014 — 0.037 
6B WT Mouse WP Aggregation 13.28 4.650 — 129.2 
6Bii WT Mouse Btk pY223 0.076 0.011 — 0.559 
6Bii WT Mouse PLCγ2 Y753 0.074 0.026 — 0.200 
6Bii WT Mouse PLCγ2 Y759 0.065 0.017 — 0.232 
6Bii WT Mouse PLCγ2 Y1217 0.122 0.044 — 0.363 
6Biii WT Mouse Syk pY525/6 - - 
6Biii WT Mouse LAT pY132 - - 
6Biii WT Mouse LAT pY200 - - 
6Biii WT Mouse Btk pY551 - - 
6Biv WT Mouse Src pY418 0.35 0.126 — 1.036 
 
Table 1: IC50 values for all dose response curves shown in figures in this study. Where no 
value is shown this indicates that the IC50 could not be calculated. 
 
 
 
 
 
 
Figure 1: Btk inhibitors completely block CLEC-2 mediated platelet aggregation in 
vitro and ex vivo. Washed platelets at 4x108/ml isolated from healthy donors (HD) were 
stimulated with 300 nM rhodocytin after incubation with ibrutinib or vehicle at the stated 
doses for 5 minutes. LTA measurements were then undertaken for 5 minutes. (A) 
Representative traces of three identical aggregation experiments. (B) Dose response curves 
(n=3). (C) PRP was isolated from the blood of patients with CLL following treatment with 
FCR, ibrutinib or acalabrutinib based chemotherapy regimens. (i) Representative trace and 
(ii) mean ± SEM (post-FCR n=5, post-ibrutinib n=12, post-acalabrutinib n=3) of optical 
density 5 minutes after stimulation with rhodocytin 10 – 300 nM. All results are shown as 
mean ± SEM. Statistical analysis was performed with a 2-way ANOVA with Tukey’s 
correction for multiple comparisons. *P<0.05, ns = non-significant. 
 
Figure 2: Btk inhibition blocks platelet adhesion to podoplanin under venous flow 
12 
conditions. Whole blood from healthy donors, patients treated with ibrutinib or acalabrutinib 
or those with XLA was incubated with DiOC6 dye for 5 minutes before being flowed across a 
capillary coated with podoplanin-Fc (100 μg/ml) at 125 s-1 for 5 minutes. Images were taken 
every second using fluorescent channels on a Zeiss Axio inverted microscope at 20X 
magnification. (A) Representative images from (i) healthy donors, patients treated with (ii) 
ibrutinib 420 mg once daily, (iii) acalabrutinib 100 mg twice daily or (iv) patients with XLA. 
Ilastik 1.1.2 machine learning software was used to automatically and reproducibly identify 
platelets. Data on platelet surface area coverage and cluster size was measured using the 
KNIME 3.4 analytics platform. Mean data ± SEM showing increase in total platelet aggregate 
area over time of (C) healthy donors (n=4) and ibrutinib treated patients (n=5) and (D) 
acalabrutinib treated patients (n=2) and those with XLA (n=2). Mean data ± SEM showing 
increase in mean aggregate size over time of (E) healthy donors and ibrutinib treated 
patients and (F) acalabrutinib treated patients and those with XLA, the curve from healthy 
donor platelets is included for comparison. Statistical analysis was performed with two-way 
ANOVA. *P<0.05, ns=non significant. 
 
Figure 3: Low concentrations of ibrutinib block all phosphorylation events 
downstream of platelet CLEC-2 ligation, blockade upstream of Btk pY223 is rescued 
by addition of excess ADP. Healthy donor washed human platelets at 4x108/ml in the 
presence of eptifibatide 9 μM were incubated with ibrutinib or vehicle for 5 minutes without 
(A) or with (B) ADP at 10µM prior to stimulation with 300 nM rhodocytin. Platelets were then 
lysed with 5X reducing sample buffer 5 minutes after addition of agonist. Whole cell lysates 
were then separated by SDS-PAGE and western blots were probed for whole cell 
phosphorylation or kinase phosphorylation with the stated antibodies downstream of the 
platelet CLEC-2 receptor. Representative blot from 4 identical experiments (i). Mean tyrosine 
levels phosphorylation level ± SEM of 4 identical experiments for phosphorylation events 
downstream (ii) and upstream (iii) of Btk pY223 as well as Src pY418 (iv). Mean aggregation 
trace from Figure 1B is included as a dotted line to aid comparison. Mean ± SEM of 3 
identical experiments for LTA measurements in the presence of ADP 5 minutes after 
stimulation with 300 nM rhodocytin are shown as a dotted line in (ii) and (iii). 
 
Figure 4: Platelets from patients with XLA do not aggregate in response to ligation of 
CLEC-2, but signalling events upstream of Btk are partially preserved. (A) PRP was 
isolated from the blood of patients with XLA and stimulated with rhodocytin. (i) 
Representative trace and (ii) mean ± SEM (healthy donor n=6, XLA n=4) of optical density 5 
minutes after stimulation with rhodocytin 300 nM. Statistical analysis was performed with a 
two-tailed t-test. (B) Eptifibatide (9 μM) treated washed platelets at 4x108/ml from patients 
with XLA were lysed with 5X reducing sample buffer 5 minutes after addition of rhodocytin 
300 nM or PBS as shown. Whole cell lysates were then separated by SDS-PAGE and 
western blots were probed for whole cell or tyrosine phosphorylation with the stated 
antibodies. (i) Blot and (ii) mean ± SEM (n=3) for phosphorylation events downstream of the 
CLEC-2 receptor. Results were analysed statistically using a one-way ANOVA with Sidak’s 
correction for multiple comparisons. 
 
Figure 5: NFAT luciferase activity in Btk deficient DT40 cells is restored with 
transfection of WT but not KD Btk. Btk deficient DT40 cells were transfected with either 
wild type (WT) or kinase dead (KD) Btk with or without CLEC-2. All cells were transfected 
with a NFAT-luciferase reporter plasmid. Cells were stimulated with rhodocytin 300 nM in the 
presence of serum. (A) Luciferase activity was measured and is shown as mean ± SEM of 
five identical experiments. Cells were stimulated with rhodocytin 50 nM in the presence or 
absence of (B) ibrutinib (0.5 – 10 μM) and (C) acalabrutinib (0.5 – 10 μM). Serum was 
excluded during stimulation to avoid plasma binding of the drugs. Luciferase activity 
between vehicle and drug treated samples was measured and is shown as the mean ± SEM 
13 
of three independent experiments. (D) CLEC-2 expression in the different transfection 
conditions. (E) Representative western blot showing Btk expression levels in cells 
transfected with different Btk constructs (n=5). *P<0.05, ns = non-significant.  
 
Figure 6: Ibrutinib blocks CLEC-2 mediated tyrosine phosphorylation of Btk pY223 at 
low concentrations in mouse platelets. Aggregation is only blocked at ~250-fold 
higher concentrations. (A) WT mouse washed platelets at 4x108/ml were incubated with 
vehicle or ibrutinib for 5 minutes prior to stimulation with rhodocytin 300 nM for 5 minutes. 
Representative trace of LTA is shown from 3 identical experiments. (B) Eptifibatide (9 μM) 
treated WT mouse washed platelets at 4x108/ml were incubated with ibrutinib or vehicle for 5 
minutes before being stimulated with rhodocytin 300 nM. Platelets were then lysed with 5X 
reducing sample buffer 5 minutes after addition of agonist. Whole cell lysates were then 
separated by SDS-PAGE and western blots were probed for whole cell phosphorylation or 
kinase phosphorylation with the stated antibodies downstream of the platelet CLEC-2 
receptor. (i) Representative blots and (ii-iv) mean results of three identical experiments 
examining degree of aggregation and tyrosine phosphorylation levels of the proteins shown. 
Mean aggregation (n=3) results are shown in (ii) and are included as dotted line in (iii-iv) to 
aid comparison. All results are shown as mean ± SEM. 
 
Figure 7: Mice dosed with ibrutinib have a trend towards reduction of thrombus 
formation in an in vivo venous thrombosis model.  WT mice were dosed with ibrutinib 
(35 – 70 mg/kg) or vehicle for 1 – 3 days before and 2 days following IVC stenosis surgery to 
achieve consistent CLEC-2 inhibition throughout the post-surgical period. (A) Heparinised 
whole was blood was taken via tail bleeding from mice undergoing the same dosing 
schedule but not undergoing surgery at the stated time points. It was incubated with FITC-
conjugated anti-P-selectin and PE-conjugated anti-activated integrin αIIbβ3 antibodies for 30 
minutes before undergoing red cell lysis and fixation and analysis using flow cytometry. 
Effect on platelet activation after stimulation with PAR4 peptide (500 nM) and rhodocytin 
(300 nM) is shown (i) representative plots, (ii) mean data ± SEM (ibrutinib n=6, vehicle n=3). 
(B) Two hours following the pre-surgical dose of ibrutinib or vehicle IVC stenosis was 
induced under general anaesthesia with a ligature. Mice were allowed to recover and were 
then culled 48 hours later and examined for the size of any IVC thrombus. (i) Thrombus 
prevalence and (ii) Thrombus length are shown (ibrutinib n=13, vehicle n=12). Horizontal line 
represents median thrombus length. Statistical analysis on thrombus prevalence was done 
with Fisher’s exact test. Statistical analysis for thrombus length was performed with Mann-
Whitney test. ns=non-significant. 
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Methods 
Reagents 
The mouse α-human CLEC-2 antibody AYP1 has been previously described29. α-LAT pAb 
(06-807) was from Merck Millipore (Burlingon, MA). Rhodocytin was isolated according a 
published protocol30, Human podoplanin-Fc has been previously described31. The Btk-
deficient DT40 cells, plasmid constructs and rabbit α-Btk antibody were a kind gift from Dr 
Mike Tomlinson (University of Birmingham, UK). FITC-conjugated anti-mouse P-selectin and 
PE-conjugated anti-mouse activated αIIbβ3 antibodies were from Emfret (Eibelstadt, 
Germany). Erythrocyte lysing agent was from Dako (Carpinteria, CA). All other reagents are 
previously described16 or are from Sigma-Aldrich (Poole, UK). 
Flow cytometry 
Heparinised whole mouse blood was obtained by femoral vein sampling and was diluted 
using phosphate buffered saline (PBS) in the presence or absence of fluorophore conjugated 
antibody before being stimulated with agonist. This was then incubated with the stated 
antibodies for 30 minutes at room temperature in the dark. Following this, erythrocytes were 
lysed and the samples were fixed. Samples were then analysed using an Accuri C6 Flow 
Cytometer (BD Biosciences, San Jose, CA). 
Flow adhesion studies 
DiOC6 labelled whole blood was flowed at 125 s-1 across podoplanin-Fc (100 μg/ml) coated 
micro-capillaries within Cellix Vena8 Fluoro+ Biochips (Cellix Limited, Dublin) as previously 
described31. 
Imaging 
Visualisation of platelet flow adhesion was performed with a 20X objective on a Zeiss Axio 
Observer 7 microscope (Carl Zeiss AG, Oberkocken, Germany).  
Image analysis 
 Flow adhesion videos were analysed using the KNIME 3.4 analytics platform (KNIME.com 
AG, Konstanz, Germany)32. Ilastik 1.1.2 machine learning software (University of Heidelberg, 
Germany) was used to automatically and reproducibly identify platelets33. 
 
DT40 cell transfection and luciferase assay 
 DT40 cells were cultured and transfected with 10 μg of CLEC-2 plasmids as well as NFAT-
luciferase and Btk plasmids as previously described16. Once transfected, cells were stimulated 
with rhodocytin 50 nM for 6 hours in the presence or absence of ibrutinib (0.5 – 10 μM), 
acalabrutinib (0.5 – 10 μM) or vehicle (DMSO) as stated. Luciferase activity was measured as 
previously described16.  
 To confirm expression of CLEC-2, cells were pelleted and resuspended in 10 μg/mL AYP1. 
Cells were washed and resuspended in AF 488-conjugated goat α-mouse antibody before 
washing. Cells were resuspended and stained with propidium iodide before flow cytometry 
analysis using a BD Accuri C6 flow cytometer.  
 To examine Btk expression, cells were washed in PBS before being pelleted. Pellets were 
resuspended in 1X RIPA buffer. 6X sample buffer was added to the sample and boiled. 
Proteins were then separated by SDS -PAGE before western blotting for Btk.  
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Supplementary Figure 1: Ibrutinib blocks CLEC-2 mediated platelet aggregation in a 
time-dependent manner. Human healthy donor washed platelets at 4x108/ml were incubated 
with ibrutinib or vehicle for 30 seconds – 60 minutes before being stimulated with rhodocytin 
300 nM for 5 minutes. (A) Representative aggregation traces from one of the five identical 
experiments. (B) Mean data ± SEM (n=5) showing the effect of ibrutinib incubation time on 
CLEC-2-mediated platelet aggregation.  
 
Supplementary Figure 2: Acalabrutinib blocks CLEC-2 mediated platelet aggregation 
and tyrosine phosphorylation in a dose dependent manner. (A) Healthy donor washed 
human platelets at 4x108/ml were incubated with acalabrutinib or vehicle (DMSO) for 5 
minutes prior to stimulation with 300 nM rhodocytin. LTA measurements were then undertaken 
for 5 minutes. (i) Representative trace. (ii) Mean data ± SEM are shown (n=3). (B) Healthy 
donor washed human platelets at 4x108/ml in the presence of eptifibatide 9 μM were incubated 
with acalabrutinib or vehicle (DMSO) for 5 minutes prior to stimulation with 300 nM rhodocytin. 
Platelets were then lysed with 5X reducing sample buffer 5 minutes after addition of agonist. 
Whole cell lysates were then separated by SDS-PAGE and western blots were probed for 
whole cell phosphorylation or kinase phosphorylation with the stated antibodies downstream 
of the platelet CLEC-2 receptor. (i) Representative blot from 4 identical experiments. (ii) Mean 
tyrosine levels phosphorylation level ± SEM of 4 identical experiments for Syk pY525/6 and 
Btk pY223. Statistical analysis with two-way ANOVA with Sidak’s correction for multiple 
comparisons. *P<0.05. 
 
Supplementary Figure 3: The Syk inhibitor PRT 060318 blocks CLEC-2 mediated 
platelet aggregation and Btk Y551 phosphorylation. Healthy donor washed human 
platelets at 4x108/ml were incubated with PRT 060318 or vehicle (DMSO) for 5 minutes prior 
to stimulation with 300 nM rhodocytin. LTA measurements were then undertaken for 5 
minutes. (A) Representative trace and (C) mean data ± SEM are shown. (B&D) ADP-sensitive 
healthy donor washed platelets at 4x108/ml were incubated, in the presence of eptifibatide (9 
μM), with PRT 060318 or vehicle for 5 minutes prior to stimulation with 300 nM rhodocytin. 
Platelets were then lysed with 5X reducing sample buffer 5 minutes after addition of agonist. 
Whole cell lysates were then separated by SDS-PAGE and western blots were probed for 
whole cell phosphorylation or kinase phosphorylation with the stated antibodies downstream 
of the platelet CLEC-2 receptor. (B) Representative blot from 3 identical experiments. (D) 
Mean tyrosine levels phosphorylation level ± SEM (n=3) for Btk pY551 and PLCγ2 pY1217. 
 
Supplementary Figure 4: Washed platelets do not aggregate in response to ADP. PRP 
and washed platelets (4x10⁸mL) isolated from healthy donors were stimulated with 0.1 – 10 
μM ADP and LTA measurements were then undertaken for 5 minutes. Dose response curves 
(n=3) are shown as mean ± SEM. 
